Key facts
- Notable investors include SND Ventures Group, Fan Zhuo Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Cellplus Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellplus Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellplus Bio
Manufacturer of advanced cell culture media and biological reagents designed to support life science and biopharmaceutical research and production. The company develops and produces a range of serum-free cell culture media, cell additives, and related biological reagents, while also offering customized media optimization and contract production services, enabling biopharmaceutical, vaccine, antibody, cell & gene therapy enterprises to achieve stable, efficient cell cultivation and reliable experimental outcomes.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- cellplusbio.com/
- Ownership
- Privately Held (backing)
Cellplus Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellplus Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellplus Bio in its N-PORT filings yet. We sweep new filings monthly.